- December 19, 2016 Spero Therapeutics Initiates First Clinical Study of Lead Potentiator Candidate for the Treatment of Multidrug Resistant Gram-Negative Infections
- November 10, 2016 Spero Therapeutics to Present at Two Upcoming November Conferences
- October 18, 2016 Spero Therapeutics Announces $1.65 Million Award from Department of Defense to Develop Novel Combination Therapy for Multidrug-Resistant, Gram-Negative Pathogens
- September 06, 2016 Spero Therapeutics to Participate in Citi’s 11th Annual Biotech Conference
- September 06, 2016 Spero Therapeutics Joins ENABLE (European Gram-negative Antibacterial Engine) Project to Combat Antibiotic-Resistant Bacteria
- August 15, 2016 Spero Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference
- June 20, 2016 Spero Therapeutics Unveils Data on Lead Potentiator Candidate for the Treatment of Multidrug Resistant Gram-Negative Infections at ASM Microbe 2016
- June 08, 2016 Spero Therapeutics to Unveil Data on Potentiator Platform at ASM Microbe 2016
- April 05, 2016 Spero Therapeutics Hires Cristina Larkin as Chief Commercial Officer
- March 02, 2016 Spero Therapeutics Hires Cristina Larkin as Chief Commercial Officer
Displaying 1 - 10 of 14 results